Patents by Inventor Xianming Deng

Xianming Deng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11932646
    Abstract: The present disclosure provides novel heteroaryl compounds of formula (VII). Such compounds are useful for the treatment of cancers.
    Type: Grant
    Filed: January 12, 2022
    Date of Patent: March 19, 2024
    Assignees: THE SCRIPPS RESEARCH INSTITUTE, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, Jianming Zhang, Barun Okram, Xianming Deng, Jae Won Chang, Amy Wojciechowski
  • Patent number: 11826365
    Abstract: The present invention relates to novel compounds which are able to modulate b-raf kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: November 28, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Hwan Geun Choi, Xianming Deng, Jianming Zhang
  • Publication number: 20230310428
    Abstract: A compound represented by the following general formula, a preparation method thereof, a pharmaceutical composition containing the compound, and a use of the compound in preparation of drugs for preventing and/or treating EGFR kinase-mediated cancers and other diseases.
    Type: Application
    Filed: May 24, 2021
    Publication date: October 5, 2023
    Applicant: HONGYUN BIOTECH CO., LTD.
    Inventors: Xianming DENG, Wei HUANG, Zhenhua WU, Yachuang WU, Caihong YUN, Jianming ZHANG, Xin HUANG
  • Publication number: 20230258841
    Abstract: The present application discloses a method for delineating exploration reserved areas of deep-sea polymetallic sulfide resources, which is suitable for delineating the exploration reserved area for further exploration by delineation and evaluation of the prospect area after prospecting and investigation of seabed sulfide. The method comprises the following: a stage of extracting prospecting indicators; a stage of evaluating metallogenic prospect areas; and, a stage of delineation of the exploration reserved areas. The present application can be applied to the evaluation and prediction of deep-sea polymetallic sulfide resources, in particular to the delineation of exploration reserved areas for deep-sea polymetallic sulfide resources.
    Type: Application
    Filed: April 18, 2023
    Publication date: August 17, 2023
    Inventors: Chunhui TAO, Shili LIAO, Guoyin ZHANG, Xianming DENG, Yuan WANG, Jin LIANG, Jianping ZHOU
  • Publication number: 20230212147
    Abstract: The present invention relates to an alkenyl pyrimidine compound, a preparation method therefor, and an application thereof. Particularly, the present invention relates to a compound having EGFR inhibitory activity and a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, a preparation method thereof, a pharmaceutical composition containing the compound, and a use of the compound in the preparation of drugs for preventing and/or treating cancer and other diseases mediated by EGFR kinase.
    Type: Application
    Filed: June 7, 2021
    Publication date: July 6, 2023
    Inventors: Xianming Deng, Wei Huang, Zhenhua Wu, Yachuang Wu, Caihong Yun, Jianming Zhang, Xin Huang
  • Publication number: 20230202986
    Abstract: Disclosed in the invention are a type of compounds having aldolase selective inhibitory activity, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for inhibiting triglyceride and cholesterol synthesis, for reducing fatty acid synthesis, for preventing and/or treating obesity and type II diabetes, for preventing and/or treating tumor, for preventing and/or treating Parkinson's disease, for preventing and/or treating Alzheimer's disease or for prolonging the lifespan of mammals:
    Type: Application
    Filed: January 17, 2023
    Publication date: June 29, 2023
    Applicant: Xiamen Vivohealths Technology Co., Ltd.
    Inventors: Xianming Deng, Shengcai Lin, Chensong Zhang
  • Patent number: 11584722
    Abstract: Disclosed in the invention are a type of compounds having aldolase selective inhibitory activity, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for inhibiting triglyceride and cholesterol synthesis, for reducing fatty acid synthesis, for preventing and/or treating obesity and type II diabetes, for preventing and/or treating tumor, for preventing and/or treating Parkinson's disease, for preventing and/or treating Alzheimer's disease or for prolonging the lifespan of mammals:
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: February 21, 2023
    Assignee: Xiamen Vivohealths Technology Co., Ltd.
    Inventors: Xianming Deng, Shengcai Lin, Chensong Zhang
  • Patent number: 11542240
    Abstract: Provided herein are compositions and methods for the treatment and prevention of cancer, including melanoma.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: January 3, 2023
    Assignees: TRUSTEES OF BOSTON UNIVERSITY, XIAMEN UNIVERSITY
    Inventors: Rutao Cui, Chengqian Yin, Xianming Deng, Ting Zhang
  • Patent number: 11414379
    Abstract: The present disclosure is concerned with N-(5-chloro-4-((4-chlorophenyl)(cyano)methyl)-2-methylphenyl)benzamide compounds that are capable of inhibiting SPAK kinase function, methods of treating hypoxic brain injuries due to, for example, ischemic stroke. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: February 16, 2021
    Date of Patent: August 16, 2022
    Assignees: UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH OF HIGHER EDUCATION, XIAMAN UNIVERSITY, UNIVERSITY OF EXETER
    Inventors: Dandan Sun, Xianming Deng, Jinwei Zhang, Mohammad Iqbal Hossain Bhuiyan, Bradley J. Molyneaux
  • Publication number: 20220242828
    Abstract: Disclosed in the invention are a type of compounds having activity of activating 5-adenosine monophosphate-activated protein kinase (AMPK), a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for reducing fatty acid synthesis, for inhibiting triglyceride and cholesterol synthesis, for preventing and/or treating obesity and type II diabetes, for preventing and/or treating tumor, for preventing and/or treating Parkinson's disease, for preventing and/or treating Alzheimer's disease or for prolonging the lifespan of mammals:
    Type: Application
    Filed: May 8, 2020
    Publication date: August 4, 2022
    Inventors: Xianming DENG, Shengcai LIN, Chensong ZHANG
  • Patent number: 11352354
    Abstract: A type of substituted penta-fused hexa-heterocyclic compounds having selective inhibition for PIKfyve kinase, a pharmaceutically acceptable salt and pharmaceutically acceptable solvate thereof, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for preventing or treating a disease associated with PIKfyve in vivo, in particular in the manufacture of a medicament for preventing or treating tumor growth and metastasis.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: June 7, 2022
    Assignee: Xiamen University
    Inventors: Xianming Deng, Wei Huang, Xihuan Sun, Ting Zhang, Zhixiang He, Yan Liu, Xinrui Wu, Baoding Zhang, Xiaoyang Li, Jingfang Zhang, Yun Chen, Li Li, Qingyan Xu, Zhiyu Hu
  • Publication number: 20220135573
    Abstract: The present disclosure provides novel heteroaryl compounds of formula (VII). Such compounds are useful for the treatment of cancers.
    Type: Application
    Filed: January 12, 2022
    Publication date: May 5, 2022
    Applicants: Dana-Farber Cancer Institute, Inc., The Scripps Research Institute
    Inventors: Nathanael S. GRAY, Jianming ZHANG, Barun OKRAM, Xianming DENG, Jae Won CHANG, Amy WOJCIECHOWSKI
  • Patent number: 11319322
    Abstract: The present invention relates to a compound having the following formula, or a stereoisomer thereof, a prodrug thereof, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, preparation method thereof, pharmaceutical composition comprising the same and use of the compound in the manufacture of a medicament for preventing or treating tumor, wherein the substituents are as defined in the specification.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: May 3, 2022
    Assignee: Xiamen University
    Inventors: Xianming Deng, Ting Zhang, Qiaofeng Kang, Yanru Yang, Xihuan Sun, Zaiyou Yang, Xiaoyang Li, Jingfang Zhang, Jiaji Zhong, Zhou Deng, Chao Dong, Shuang Liu, Li Li, Qingyan Xu, Zhiyu Hu
  • Patent number: 11292787
    Abstract: The invention relates to the field of medicinal chemistry, and to five-membered-fused-six-membered aza-aromatic ring compound, preparation method thereof, pharmaceutical composition and application thereof. In particular, the invention relates to a type of compounds capable of specifically enhancing ubiquitination degradation of Ras proteins, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for preventing or treating a disease associated with Ras activity in vivo, in particular in the manufacture of a medicament for preventing or treating tumor growth and metastasis.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: April 5, 2022
    Assignee: Xiamen University
    Inventors: Xianming Deng, Hongrui Wang, Taoling Zeng, Ting Zhang, Tingting Jiang
  • Patent number: 11254682
    Abstract: The present disclosure provides novel heteroaryl compounds of formula (IV). Such compounds are useful for the treatment of cancers.
    Type: Grant
    Filed: July 20, 2020
    Date of Patent: February 22, 2022
    Assignees: THE SCRIPPS RESEARCH INSTITUTE, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, Jianming Zhang, Barun Okram, Xianming Deng, Jae Won Chang, Amy Wojciechowski
  • Publication number: 20210261497
    Abstract: The present disclosure is concerned with N-(5-chloro-4-((4-chlorophenyl)(cyano)methyl)-2-methylphenyl)benzamide compounds that are capable of inhibiting SPAK kinase function, methods of treating hypoxic brain injuries due to, for example, ischemic stroke. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: February 16, 2021
    Publication date: August 26, 2021
    Inventors: Dandan Sun, Xianming Deng, Jinwei Zhang, Mohammad Iqbal Hossain Bhuiyan, Bradley J. Molyneaux
  • Patent number: 11078213
    Abstract: The present invention relates to thienopyrimidine compound, preparation method thereof, pharmaceutical composition and use thereof, and in particular to a type of compounds having ALK and/or c-Met selective inhibitory activity, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for preventing or treating a disease associated with anaplastic lymphoma kinase in vivo, and in the manufacture of a medicament for preventing or treating a disease associated with angiogenesis or cancer metastasis, in particular in the manufacture of a medicament for preventing or treating tumor growth and metastasis.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: August 3, 2021
    Assignee: HONGYUN BIOTECH CO., LTD.
    Inventors: Xianming Deng, Baoding Zhang, Shuang Liu, Chao Dong, Xihuan Sun, Xiaoxing Huang, Zhou Deng, Yunzhan Li, Yue Lu, Li Li, Zhiyu Hu
  • Publication number: 20210228552
    Abstract: Provided is use of E3 ubiquitin ligase Nedd4-1 in preparation of a drug for inhibiting the Ras protein level. Also provided is use in preparation of a drug for preventing and/or treating tumors or a drug for prolonging the life span of organisms.
    Type: Application
    Filed: April 25, 2019
    Publication date: July 29, 2021
    Applicant: Xiamen University
    Inventors: Hongrui WANG, Xianming DENG, Taoling ZENG, Tingting JIANG
  • Patent number: 10995061
    Abstract: The present disclosure is concerned with N-(5-chloro-4-((4-chlorophenyl)(cyano)methyl)-2-methylphenyl)benzamide compounds that are capable of inhibiting SPAK kinase function, methods of treating hypoxic brain injuries due to, for example, ischemic stroke. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: May 4, 2021
    Assignees: United States Government as Represented by the Department of Veterans Affairs, The University of Pittsburgh—of the Commonwealth of Higher Education, Xiamen University, University of Exeter
    Inventors: Dandan Sun, Xianming Deng, Jinwei Zhang, Mohammad Iqbal Hossain Bhuiyan, Bradley J. Molyneaux
  • Patent number: 10975092
    Abstract: The present invention relates to compounds (I) capable of inhibiting the Mst1/2 protein kinase activity, a preparation method therefor, a pharmaceutical composition comprising the compounds, and uses of the compounds and the pharmaceutical composition comprising the compounds in the preparation of drugs for prompting repair and regeneration of tissues and organs, prompting stem cell proliferation and somatic cell dedifferentiation, immunosuppression, and preventing or treating diseases related to nervous disorders and local ischemia.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: April 13, 2021
    Assignee: Anhui New Star Pharmaceutical Development Co., Ltd.
    Inventors: Xianming Deng, Dawang Zhou, Lanfen Chen, Zhixiang He, Fuqin Fan